Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SANA BIOTECHNOLOGY, INC.

(SANA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/13/2022 01/14/2022 01/18/2022 01/19/2022 01/20/2022 Date
11.52(c) 11.37(c) 9.85(c) 9.16(c) 8.85(c) Last
963 928 1 302 626 1 326 696 1 987 350 1 415 681 Volume
-2.70% -1.30% -13.37% -7.01% -3.38% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -319 M - -
Net cash position 2021 580 M - -
P/E ratio 2021 -4,71x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -411 M - -
Net cash position 2022 381 M - -
P/E ratio 2022 -4,02x
Yield 2022 -
Capitalization 1 620 M 1 620 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 354
Free-Float -
More Financials
Company
Sana Biotechnology, Inc is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic... 
More about the company
Ratings of Sana Biotechnology, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about SANA BIOTECHNOLOGY, INC.
01/11Sana Secures Exclusive License to NIH's CD22 Cancer Drug
MT
01/11SANA BIOTECHNOLOGY, INC. : Entry into a Material Definitive Agreement, Regulation FD Discl..
AQ
01/11Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD2..
GL
01/10Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive..
GL
01/10Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive..
GL
01/04Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021SANA BIOTECHNOLOGY, INC.(NASDAQGS : SANA) added to NASDAQ Biotechnology Index
CI
2021Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Pla..
AQ
2021Sana Biotechnology Q3 Loss Narrows
MT
2021SANA : Q3 Earnings Snapshot
AQ
2021Sana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates - ..
PU
2021SANA BIOTECHNOLOGY, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
2021Earnings Flash (SANA) SANA BIOTECHNOLOGY Posts Q3 Loss $-0.37
MT
2021Sana Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
2021Sana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates
AQ
More news
News in other languages on SANA BIOTECHNOLOGY, INC.
2021La perte de Sana Biotechnology au troisième trimestre diminue
2021Sana Biotechnology signe un accord portant sur les droits commerciaux non exclusifs de ..
2021Illumina nomme Bob Ragusa au poste de PDG de GRAIL
2021MaxCyte accorde à Sana Biotechnology les droits commerciaux sur sa technologie d'ingéni..
2021Sana Biotechnology signe un bail pour la mise en place d'une installation de fabricatio..
More news
Analyst Recommendations on SANA BIOTECHNOLOGY, INC.
More recommendations
Chart SANA BIOTECHNOLOGY, INC.
Duration : Period :
Sana Biotechnology, Inc. Technical Analysis Chart | SANA | US7995661045 | MarketScreener
Technical analysis trends SANA BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 8,85 $
Average target price 36,25 $
Spread / Average Target 310%
EPS Revisions
Managers and Directors
Steven D. Harr President & Chief Executive Officer
Nathan Hardy Chief Financial Officer & Senior Vice President
Hans Edgar Bishop Chairman
Sunil Agarwal Chief Medical Officer, EVP & Head-Development
Stacey Ma EVP & Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
SANA BIOTECHNOLOGY, INC.-42.83%1 620
MODERNA, INC.-34.04%67 921
LONZA GROUP AG-13.71%53 315
IQVIA HOLDINGS INC.-13.38%46 690
SEAGEN INC.-13.93%24 331
ICON PUBLIC LIMITED COMPANY-17.37%20 831